Open AccessLongitudinal Electrocardiographic Evaluation of Dogs with Degenerative Mitral Valve Disease
Author(s) -
LópezAlvarez J.,
Boswood A.,
Moonarmart W.,
Hezzell M.J.,
Lotter N.,
Elliott J.
Publication year - 2014
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/jvim.12311
Subject(s) - medicine , disease , prospective cohort study , heart rate , mitral valve , heart disease , mortality rate , sudden death , cardiology , blood pressure
Background Increased heart rate ( HR ) and decreased heart rate variability ( HRV ) are evident in some dogs with degenerative mitral valve disease ( DMVD ). Objectives Evaluation of the factors influencing HR and HRV (assessed by the vasovagal tonus index; VVTI ) and their change over time in dogs with DMVD . Animals Client‐owned dogs (n = 257) with DMVD recruited from first opinion practice. Methods Prospective longitudinal follow‐up at six‐monthly intervals of dogs with DMVD . Dogs followed up for at least 18 months (n = 102) were grouped according to their outcome as dogs dying/euthanized because of cardiac disease (n = 28; Group 1), noncardiac disease (n = 40; Group 2) and dogs alive (n = 34; Group 3). HR and VVTI were measured on 1‐minute ECG recordings. Repeated measures linear models were constructed to investigate the factors that influence HR and VVTI and their changes over time. Results Heart rate and VVTI were affected by disease severity and were different in Cavaliers compared to other breeds. Group 1 and Group 2 dogs underwent an increase in HR and decrease in VVTI , evident at least 18 months before death. Group 1 had a further decrease in VVTI followed by an increase in HR approximately 1 year and 6 months before death, respectively. Conclusions and Clinical Importance Dogs with DMVD have an increase in HR and decrease in HRV over a year before death, with greater changes in those dogs dying/euthanized because of cardiac disease. Both HR and VVTI can potentially be regarded as biomarkers for all‐cause mortality.